Supported by the International Myopia Institute. The publication and dissemination costs of the International Myopia Institute reports were supported by donations from the Brien Holden Vision Institute, Carl Zeiss Vision, CooperVision, EssilorLuxottica, Hoya, Thea, Alcon, and Oculus. A special acknowledgement to Christine Wildsoet for harmonization of this white paper.
Disclosure: P. Sankaridurg, EssilorLuxottica (F, R), Shamir (F), CooperVision (F, R), SEED (R), Oculus (F), SightGlass Vision (R), Mark Ennovy (R), Myopia Control- optical and pharmaceutical (P), ZEISS (C); D.A. Berntsen, Bausch & Lomb (F); M.A. Bullimore, Alcon Research (C), CooperVision (C), Corneagen (C), EssilorLuxottica (C), Euclid Systems (C), Eyenovia (C), Genentech (C), Johnson & Johnson Surgical (C), Johnson & Johnson Vision (C), Lentechs (C), Novartis (C), Oculus(C), Pentavision (C), Presbia (C), Vyluma (C), Ridgevue Publishing (O), Ridgevue Vision (O); P. Cho, Johnson and Johnson Vision (C), Menicon (C); I. Flitcroft, CooperVision (C), EssilorLuxottica (C), Johnson & Johnson Vision (C), Vyluma (C), Thea (C), Ocumetra (O), Myopia control monitoring tools and devices (P); T.J. Gawne, P (patents pending for several optical methods for myopia control); K.L. Gifford, Alcon (C), CooperVision (C), EssilorLuxottica (C), Hoya Vision (C), Johnson & Johnson Vision (C), Menicon (C), SightGlass Vision (C), Topcon Healthcare (C), OCULUS (C), Visioneering Technologies (C), Vyluma (C); M. Jong, Johnson&Johnson Vision (E); P. Kang, Coopervision (F), Johnson and Johnson (F); L.A. Ostrin, (N); J. Santodomingo-Rubido, Menicon Co Ltd €; C. Wildsoet, (N); J.S. Wolffsohn, AOS (C), Aston Vision Sciences (S), Bausch & Lomb (C), Alcon (C, F), Allergan (F), CooperVision (C, F), CSIDryEye (C), DopaVision, Eyoto (S), Johnson & Johnson Vision (F), Rayner (F), M2C Pharmaceuticals (C, F), Medmont (C), Novartis (C, F), NuVision (C, F), Santen (C), Scope Ophthalmics (C, F), Sight-Glass (C, F), Théa (C, F), Topcon (F), The Eye Doctor (F), Wolffsohn Research Limited (S)